Roche Sales Beat Masks Thin Pipeline Proof in Q3 2026 Update

Roche Reports Strong Q3 Sales and Multiple Key Approvals

Roche reported robust financial performance in the third quarter of 2026, with Group sales increasing +7% at constant exchange rates (CER) and +8% in CHF, contributing to a +6% CER growth for the first nine months to CHF 46.5 billion. This growth was driven by strong demand across both its Pharmaceuticals and Diagnostics Divisions. The company also announced multiple significant regulatory approvals in the US and EU, alongside positive clinical data readouts for several pipeline assets, underscoring its continued progress in delivering innovative healthcare solutions.

• Strong Financial Performance: Roche's Group sales for the first nine months of 2026 reached CHF 46.5 billion, a +6% increase at CER, with Q3 sales alone growing +7% at CER. The Pharmaceuticals Division contributed CHF 36.2 billion (+7% CER), propelled by top growth drivers like Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo, while the Diagnostics Division grew +4% at CER to CHF 10.3 billion.
• Key Regulatory Milestones: Roche secured several important approvals, including US FDA approval for Tecentriq in adjuvant stage-III DNA mismatch repair colon cancer, Gazyva/Gazyvaro for childhood-onset idiopathic nephrotic syndrome, and Enspryng for thyroid eye disease. Additionally, Susvimo received EU approval for neovascular age-related macular degeneration, and fenebrutinib was granted US FDA Priority Review for both relapsing and primary progressive multiple sclerosis.
• Advancing Clinical Pipeline: Positive phase III data were reported for Lunsumio in follicular lymphoma (CELESTIMO study) and Tam-Peli in relapsed small-cell lung cancer, showing significant improvements in progression-free and overall survival, respectively. Interim phase III data for sefaxersen in IgA nephropathy demonstrated significant proteinuria reduction, while phase II results for enicepatide showed best-in-disease potential for glycaemic control and weight loss in type 2 diabetes and obesity.
• Diagnostics Innovation and Strategic Investments: The US FDA cleared the Elecsys pTau217 test, the first single-biomarker blood test for Alzheimer’s disease, enhancing diagnostic capabilities. Roche also announced significant investments, including a USD 750 million expansion of its Hillsboro injectable medicines facility and the grand opening of its Innovation Center Boston, focusing on cardiovascular, renal, and metabolic diseases.

Addressing Key Challenges in Stage-III dMMR Colon Cancer

Stage-III dMMR colon cancer retains a good prognostic phenotype, but the survival advantage is probably more pronounced for stage II than stage III tumor, complicating adjuvant decision-making. Current management centers on fluoropyrimidine plus oxaliplatin, yet efficacy is uneven across endpoints and the optimal duration, regimen, and patient selection remain unresolved.

• Lack of efficacy of 5-fluorouracil alone: Deficient mismatch repair colon cancer is reportedly resistant to 5-fluorouracil adjuvant chemotherapy, and microsatellite instability status would predict the lack of efficacy of adjuvant 5-fluorouracil chemotherapy. As compared with surgery alone, adjuvant fluoropyrimidine alone did not improve disease-free survival in multivariable analysis (HR = 0.73, 95% CI = 0.36 to 1.49, P = .38).

• Dependence on oxaliplatin combination with divergent survival signals: Microsatellite instability tumors would have a survival benefit with the addition of oxaliplatin to adjuvant 5FU chemotherapy. As compared with surgery alone, adjuvant oxaliplatin-based chemotherapy improved disease-free survival in multivariable analysis (HR = 0.35, 95% CI = 0.19 to 0.65, P < .001), with the DFS benefit statistically significant in multivariable analysis only in stage III (HR = 0.41, 95% CI = 0.19 to 0.87, P = .02). In stage III MSI-H/dMMR disease, overall survival was improved with any adjuvant chemotherapy vs. any control arm (HR 0.42, 95% CI 0.26-0.66; P < 0.01), while DFS was not significantly improved (HR 0.7, 95% CI 0.45-1.09; P = 0.11).

• Unresolved regimen, duration, and patient fitness considerations: The duration of the adjuvant treatment (3 or 6 months) and the regimen used (FOLFOX or XELOX) should be based on the recommendations of the international IDEA consortium pending the results of the translational studies of this trial. Discussion of adjuvant treatment in MSI tumors should also include other factors such as the patient's age and comorbidities.

• Biologic heterogeneity and predictors of poor chemotherapy response: BRAF mutation was prognostic for overall survival, particularly in patients with MSI-low and stable tumors (hazard ratio, 2.2; 95% CI, 1.4 to 3.4; P = .0003), and the V600E BRAF mutation confers a worse prognosis to stage II and stage III colon cancer patients independently of disease stage and therapy. Increased expression of osteopontin (p = 0.019) and low density of CD8-positive T-cells (p = 0.043) were significantly associated with unfavourable response to 5-FU, and miR-1290 was positively correlated with dMMR status and predicted poor prognosis in stage II and III colon cancer patients who received 5-FU-based chemotherapy.

• Investigational role of immunotherapy in early-stage disease: The promising results of immunotherapy in metastatic MSI colorectal led to the development of clinical trials evaluating "immune checkpoint blockers" in combination with FOLFOX in the treatment of stage III MSI colon cancer.

The ATOMIC Study: Design and Endpoints for Adjuvant Tecentriq

Perioperative and neoadjuvant immune checkpoint inhibition is being evaluated as a chemotherapy-free option for resectable dMMR/MSI-H colon cancer. Evidence spans an ongoing global Phase III randomized study and prospective Phase 2 trials and real-world series in stage II-III disease, centered on pathological response, clinical complete response, and event-free survival endpoints.

Tecentriq's New Role in Stage-III dMMR Colon Cancer Standard of Care

In stage III colon cancer, standard treatment consists of a combination of fluoropyrimidine (oral or intravenous) with oxaliplatin for 6 months, although administration of CAPOX can be considered for 3 months in low-risk tumors. Universal MMR testing is mandatory, with deficient MMR (dMMR)/microsatellite instability-high (MSI-H) tumors representing approximately 15% of stage II/III cases, and it is mandatory to determine MSI/MMR status for avoiding administering fluoropyrimidines in monotherapy to patients with MSI-H/dMMR tumors. Adjuvant therapy significantly improved disease-free survival (DFS) (hazard ratio [HR], 0.67; 95% CI, 0.48 to 0.93; P = .02) in patients with proficient mismatch repair (pMMR) tumors, while patients with dMMR tumors receiving fluorouracil (FU) had no improvement in DFS (HR, 1.10; 95% CI, 0.42 to 2.91; P = .85) compared with those randomly assigned to surgery alone, and in resected, dMMR/MSI-H stage II colorectal cancer (CRC), adjuvant fluoropyrimidine has no benefit and is not recommended.

For stage III disease, the phase III ATOMIC trial demonstrated that adding atezolizumab to mFOLFOX significantly improved 3-year disease-free survival (DFS) versus chemotherapy alone (86.4% vs. 76.6%; HR 0.50; 95% CI 0.34-0.72). The POLEM trial is recruiting patients with completely resected, stage III colon cancer confirmed to have dMMR/MSI-H or POLE exonuclease domain mutation, randomized in a 1:1 ratio to standard fluoropyrimidine-based chemotherapy (capecitabine, oxaliplatin for 12 weeks or capecitabine for 24 weeks) or chemotherapy followed by avelumab (10 mg/kg, 2 weekly for 24 weeks), with DFS as the primary endpoint and a control 3-year DFS rate expected to be ~75% versus 87% with avelumab.

Neoadjuvant treatment is not consolidated yet although immunotherapy is achieving very good preliminary results in MSI-H patients, including neoadjuvant nivolumab plus ipilimumab with pathological response in 109 of 111 patients (98%; 95% CI, 94 to 100), including 105 (95%) with a major pathological response and 75 (68%) with a pathological complete response. The use of ctDNA to define the treatment and monitoring of resected tumors is only recommended within studies, although plasma ctDNA offers a window to gauge efficacy of oxaliplatin-based adjuvant chemotherapy to clear microscopic disease, with failure to clear minimal residual disease prompting change to immune checkpoint blockade with pembrolizumab and resultant ctDNA clearance in reported dMMR/MSI-H stage III cases.

Roche's Innovation Engine: Reshaping Treatment Paradigms with Multi-Targeted Therapies

Roche's recent financial results, underscored by significant regulatory approvals and positive clinical data, paint a picture of a pharmaceutical powerhouse effectively leveraging its innovation engine. This robust performance is not merely about sales figures; it reflects a strategic advancement in addressing critical unmet medical needs across diverse therapeutic areas.

A prime example is the continued impact of faricimab, a bispecific antibody that targets both VEGF-A and Ang-2. Its demonstrated long-term durability and ability to extend dosing intervals are fundamentally reshaping the treatment paradigm for neovascular age-related macular degeneration and diabetic macular edema. This innovation significantly reduces the treatment burden for patients while maintaining or improving visual and anatomical outcomes, a crucial differentiator in a competitive market. However, the ongoing influx of new anti-VEGF agents and alternative treatment strategies means that sustained market leadership will depend on continuous evidence of superior long-term efficacy and patient adherence.

In oncology, the notable efficacy of mosunetuzumab in relapsed/refractory diffuse large B-cell lymphoma, particularly for patients previously treated with CAR-T therapy, highlights the transformative potential of bispecific antibodies in challenging hematologic malignancies. This success is complemented by the strengthening of the immuno-oncology portfolio through atezolizumab-based combinations, especially in hepatocellular carcinoma. While the prior setbacks of TIGIT inhibitors like tiragolumab serve as a reminder of the inherent risks in novel pathway development, they also underscore the importance of precise patient selection and combination strategies to unlock the full potential of next-generation immunotherapies.

Furthermore, the approval of remibrutinib, a novel Bruton's tyrosine kinase inhibitor, for chronic spontaneous urticaria marks a strategic expansion into inflammatory diseases. This offers a new therapeutic avenue for patients refractory to existing treatments. Yet, the history of other BTK inhibitors being discontinued due to safety or efficacy concerns emphasizes the need for vigilant post-market surveillance and clear differentiation to ensure long-term success and patient safety within this class. Collectively, these advancements demonstrate a clear strategic focus on developing precision-targeted, multi-mechanism therapies, positioning the company for continued growth while navigating the complexities of drug development and market competition.